Description

IVERHUMAN 12 MG

Indications

IVERHUMAN 12 MG is primarily indicated for the treatment of various parasitic infections. It is commonly used to manage conditions such as strongyloidiasis, onchocerciasis, and other helminthic infections. The active ingredient, Ivermectin, is effective against a broad spectrum of parasites, making it a valuable option in both clinical and community settings. Additionally, it may be utilized in the treatment of certain ectoparasitic infestations, including scabies and lice, thereby providing a comprehensive approach to parasitic diseases.

Mechanism of Action

The mechanism of action of IVERHUMAN 12 MG is primarily attributed to its ability to bind selectively to glutamate-gated chloride channels in the nerve and muscle cells of invertebrates. This binding leads to an increase in the permeability of the cell membrane to chloride ions, causing hyperpolarization of the cells. As a result, the parasites experience paralysis and eventual death. Furthermore, Ivermectin also affects other ion channels, such as gamma-aminobutyric acid (GABA) receptors, contributing to its antiparasitic efficacy. This dual action makes IVERHUMAN particularly effective against a wide range of parasitic organisms.

Pharmacological Properties

IVERHUMAN 12 MG exhibits a favorable pharmacokinetic profile. After oral administration, Ivermectin is rapidly absorbed, with peak plasma concentrations typically occurring within 4 to 5 hours. The drug is highly lipophilic, which facilitates its distribution throughout the body, including the central nervous system. Ivermectin is metabolized predominantly in the liver, with a half-life ranging from 12 to 36 hours, allowing for sustained therapeutic effects. The drug is excreted mainly in the feces, with minimal renal elimination. This pharmacological profile supports its use in single-dose regimens for many indications.

Contraindications

IVERHUMAN 12 MG is contraindicated in individuals with a known hypersensitivity to Ivermectin or any of the excipients in the formulation. It should not be administered to patients with conditions that may lead to increased risk of adverse effects, such as those with severe liver impairment or those who are pregnant or breastfeeding without medical supervision. Caution is also advised in patients with neurological disorders, as the drug’s effects on the central nervous system may exacerbate these conditions.

Side Effects

While IVERHUMAN 12 MG is generally well-tolerated, some patients may experience side effects. Commonly reported adverse reactions include dizziness, nausea, diarrhea, and fatigue. In rare cases, more severe effects such as hypotension, seizures, or allergic reactions may occur. Patients should be monitored for any unusual symptoms following administration, and healthcare providers should be informed of any pre-existing conditions that may predispose individuals to increased risk of side effects.

Dosage and Administration

The recommended dosage of IVERHUMAN 12 MG varies based on the specific condition being treated and the patient’s weight. For most parasitic infections, a single oral dose is typically sufficient. For example, the standard dose for strongyloidiasis is 200 micrograms per kilogram of body weight. It is essential to follow the prescribing physician’s instructions and to not exceed the recommended dosage. Patients should take the medication with water on an empty stomach for optimal absorption. In cases of reinfection, retreatment may be necessary, and the healthcare provider will determine the appropriate timing.

Interactions

IVERHUMAN 12 MG may interact with other medications, potentially altering its effectiveness or increasing the risk of adverse effects. Notably, concomitant use of Ivermectin with medications that affect the central nervous system, such as benzodiazepines or barbiturates, may enhance sedative effects. Additionally, drugs that induce or inhibit liver enzymes (particularly CYP3A4) may affect the metabolism of Ivermectin. Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Before initiating treatment with IVERHUMAN 12 MG, it is crucial to conduct a thorough medical evaluation. Patients with a history of liver disease, neurological disorders, or those who are immunocompromised should use this medication with caution. Regular monitoring may be necessary to assess for any adverse effects or complications. It is also important to consider the potential for drug resistance in treating parasitic infections, and healthcare providers should remain vigilant in monitoring treatment outcomes.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy and safety of IVERHUMAN 12 MG in treating various parasitic infections. Research published in peer-reviewed journals has shown that Ivermectin is effective in achieving high cure rates for conditions such as onchocerciasis and lymphatic filariasis. In a randomized controlled trial, subjects treated with Ivermectin exhibited significant reductions in parasite load compared to placebo groups. Additionally, studies have indicated that Ivermectin is well-tolerated, with a low incidence of serious adverse effects, reinforcing its role as a first-line treatment option for many parasitic infections.

Conclusion

IVERHUMAN 12 MG is an effective and well-established treatment for a variety of parasitic infections. Its unique mechanism of action, favorable pharmacokinetic properties, and broad spectrum of activity make it a valuable therapeutic agent. While generally safe, it is essential for healthcare providers and patients to remain aware of potential side effects, contraindications, and drug interactions. Ongoing research and clinical studies continue to support the use of IVERHUMAN in managing parasitic diseases, highlighting its importance in public health.